Fludarabine
Blasts 10 Percent or More of Bone Marrow Nucleated Cells
Sumithira VasuSmall moleculePhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 32/ 100
- Competitive Position
- 95/ 100
Competitive context
16 Active assets in the Blasts 10 Percent or More of Bone Marrow Nucleated Cells cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Fludarabine Sumithira Vasu | Phase 2 | BB |
Gilteritinib Stichting Hemato-Oncologie voor Volwassenen Nederland | Phase 3 | BB |
Cytosin-Arabinosid Sumithira Vasu | Phase 2 | BB |
Midostaurin Stichting Hemato-Oncologie voor Volwassenen Nederland | Phase 3 | B |
Thiotepa Fred Hutchinson Cancer Center | Phase 2 | B |
View all 29 →
Same molecule, other indications
Fludarabine is also rated in:
acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22)Dormant
BBB
Indicative ·
76 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →